SUWANEE, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (OTCQB: SNWV), focused on the development and commercialization of a robust and innovative advanced wound care product portfolio for the repair and regeneration of skin and vascular structures, today announced its rebranding. The new brand reflects the evolution of SANUWAVE’s solutions addressing the entire wound care pathway through its portfolio of noninvasive and biological response therapeutics that help expedite the wound healing process at the cellular level, resulting in less time and resources spent on more costly treatments.
The combination of SANUWAVE’s dermaPACE® System and the UltraMIST® System – acquired from Celularity, Inc., in 2020 – is the basis for its “Energy First” protocol for wound healing. Additionally, premium licensing of two important biologics from Cellularity – BIOVANCE® Human Amniotic Membrane Allograft and Interfyl® Human Connective Tissue Matrix – add to a portfolio of solutions that improve clinical outcomes across the continuum of wound care.
“In light of our growth and expansion, we are excited to launch SANUWAVE’s new brand, featuring our complete line of healing systems and biologics offerings,” said SANUWAVE CEO & Chairman of the Board Kevin A. Richardson, II. “Our Energy First approach enables us to provide effective treatment options for patients requiring advanced wound care, closure, and healing. We invite everyone to visit our new website and explore what today’s SANUWAVE has to offer.”
SANUWAVE Health is focused on the research, development, and commercialization of its patented, noninvasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic, and cardiac/endovascular conditions.
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.